MindWalk Holdings (HYFT) Cash from Financing Activities (2023 - 2026)
MindWalk Holdings (HYFT) reported Cash from Financing Activities of -$9.6 million for Q1 2026, down 229.06% year-over-year from $7.4 million in Q1 2025, and down 194.48% quarter-over-quarter from $10.1 million in Q4 2025.
MindWalk Holdings (HYFT) Cash from Financing Activities (2023 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has 4 years of Cash from Financing Activities data on file, last reported at -$9.6 million in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at -$9.6 million, down 229.06% year-over-year; the trailing twelve-month figure through Jan 2026 was -$3835.7 (down 100.03% YoY), and the FY2025 annual result was $10.7 million, up 1319.84% from the prior year.
- Cash from Financing Activities fell to -$9.6 million in Q1 2026 per HYFT's latest filing, from $10.1 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $10.1 million in Q4 2025 and troughed at -$9.6 million in Q1 2026.
- A 4-year average of $859081.5 and a median of -$209073.2 in 2023 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities jumped 1538.31% in 2025, then slumped 229.06% in 2026.
- A 4-year view of Cash from Financing Activities shows it stood at -$228623.1 in 2023, then surged by 762.71% to $1.5 million in 2024, then surged by 569.78% to $10.1 million in 2025, then slumped by 194.48% to -$9.6 million in 2026.
- Business Quant data shows HYFT's Cash from Financing Activities at -$9.6 million in Q1 2026, $10.1 million in Q4 2025, and -$270008.4 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 85,464.43 |
| 10 | MindWalk Holdings | 166.20 Mn | 156.06 Mn | 1.78 | -9.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | -9.59 Mn |
| Jan 31, 2026 | -9.59 Mn |
| Oct 31, 2025 | 10.15 Mn |
| Oct 31, 2025 | 10.15 Mn |
| Jul 31, 2025 | -270,008.36 |
| Jul 31, 2025 | -270,008.36 |
| Apr 30, 2025 | -293,740.59 |
| Apr 30, 2025 | -293,740.59 |
| Jan 31, 2025 | 7.43 Mn |
| Jan 31, 2025 | 7.43 Mn |
| Oct 31, 2024 | 1.52 Mn |
| Oct 31, 2024 | 1.52 Mn |
| Jul 31, 2024 | 1.97 Mn |
| Jul 31, 2024 | 1.97 Mn |
| Apr 30, 2024 | 828,235.27 |
| Apr 30, 2024 | 828,235.27 |
| Jan 31, 2024 | 453,449.27 |
| Jan 31, 2024 | 453,449.27 |
| Oct 31, 2023 | -228,623.11 |
| Oct 31, 2023 | -228,623.11 |